Adrian W Quartel

CIK 1910132 · Chief Medical Officer · last filed 2026-07-29

Adrian W Quartel is a Chief Medical Officer who has filed 6 SEC Form 4 insider transactions across 3 companies since 2022. The most recent filing, for SPRB, was dated Jul 29, 2026. Across all open-market trades the lifetime net is −$40.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $88.7K across reported positions. 1 Form 144 notice of planned sales is also on file; the latest, for ZVRA on Jan 30, 2026, lists the filer as an officer.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$88.7K
Companies
3
Total Filings
6
Lifetime Open-Market Net
-$40.0K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

ZVRA price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
300 WASHINGTON STREET
ONE GATEWAY CENTER, SUITE 351
NEWTON, MA 02458
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SPRB Chief Medical Officer — $40.34 — $0 1 2026-07-29
ZVRA Chief Medical Officer 9,723 $9.12 $88.7K -$40.0K 2 2026-02-02
Acer Therapeutics Inc. (ACER) Delisted Chief Medical Officer — $0.66 — $0 2 2023-03-16

10b5-1 Trading Plans

2 plans · 1 in force
Plans this person adopted or ended, as the company reported them in its 10-Q or 10-K. A Rule 10b5-1 plan sets trades in advance; a director's or officer's plan can't sell until a cooling-off period ends, 90 to 120 days after adoption. Sold so far adds up the open-market sales filed on Form 4 under a plan since it was adopted, and the percentage is of the shares the plan allows.
Company Adopted Sales Can Start Ends Plan Allows Sold So Far Status Link
ZVRA
Chief Medical Officer
Mar 16, 2026 Jun 14, 2026 Apr 30, 2027 225,000 shares None filed Active 10-Q
ZVRA
Chief Medical Officer
Mar 26, 2025 Jun 24, 2025 Ended Mar 31, 2026 79,533 shares 4,533 (6%)
last filed Feb 2, 2026
Ended early 10-Q
Sales can start: the later of 90 days after adoption and two business days after the report for the quarter it was adopted in, capped at 120 days. Ends: the end date the company gave, or adoption plus the plan's stated length; a plan can also end sooner once its shares are sold. Ended early means the company reported the plan terminated before that date. Sold so far is left blank while a plan is cooling off, and when a stock split falls inside the plan the percentage is left out because the limit is in pre-split shares.

Recent Filings

6 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2026-07-29 SPRB Grant (A) — $0 EDGAR
2026-02-02 ZVRA Mixed10b5-1
Plan adopted Mar 26, 2025
+6,800 -$40.0K EDGAR
2026-01-30 ZVRA Notice (144)
Officer · Planned Jan 30, 2026 · 10b5-1 plan
Sold: Form 4 filed Feb 2, 2026
−4,533 -$40.2K EDGAR
2025-03-27 ZVRA Grant (A) — $0 EDGAR
2023-03-16 Acer Therapeutics Inc. (ACER) Delisted Grant (A) — $0 EDGAR
2022-02-23 Acer Therapeutics Inc. (ACER) Delisted Grant (A) — $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).